Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 2/20 | 0.45 |
| ▸ | FNTB | P49356 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8203891 | 0.88 | TAAR1 (0.54) | TAAR1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL8204699 | 0.85 | TAAR1 (0.57) | TAAR1FNTAFNTBCYP2C9 | |
| SCHEMBL8210141 | 0.83 | ALDH1A1 (0.46) | TAAR1KMT2ACYP2C9HRH3 | |
| SCHEMBL8204147 | 0.80 | CHRM2 (0.44) | TAAR1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL8202717 | 0.77 | HSD11B1 (0.47) | TAAR1FNTAFNTBKMT2AHRH3 | |
| SCHEMBL29659985 | 0.76 | MTNR1A (0.56) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL22262519 | 0.76 | MTNR1A (0.56) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL22262517 | 0.76 | MTNR1A (0.56) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL1736523 | 0.75 | CHRM2 (0.45) | TAAR1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL1736521 | 0.75 | CHRM2 (0.45) | TAAR1CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858652-B2 | Substituted 4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858652-B2 | Substituted 4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20080139533-A1 | SUBSTITUTED 4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
| US-20080139533-A1 | SUBSTITUTED 4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
| WO-2008058867-A2 | SUBSTITUTED 4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139533-A1 | SUBSTITUTED 4-IMIDAZOLES | TAAR1, TAAR5, TACR1 | TAAR1 1/4885CHRM2 70/4885CHRM4 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.